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The use of serum or plasma for Aspergillus PCR testing facilitates automated and standardized technology. Recommendations
for serum testing are available, and while serum and plasma are regularly considered interchangeable for use in fungal diagnos-
tics, differences in galactomannan enzyme immunoassay (GM-EIA) performance have been reported and are attributed to clot
formation. Therefore, it is important to assess plasma PCR testing to determine if previous recommendations for serum are ap-
plicable and also to compare analytical performance with that of serum PCR. Molecular methods testing serum and plasma were
compared throughmulticenter distribution of quality control panels, with additional studies to investigate the effect of clot for-
mation and blood fractionation on DNA availability. Analytical sensitivity and time to positivity (TTP) were compared, and a
regression analysis was performed to identify variables that enhanced plasma PCR performance. When testing plasma, sample
volume, preextraction-to-postextraction volume ratio, PCR volume, duplicate testing, and the use of an internal control for PCR
were positively associated with performance. When whole-blood samples were spiked and then fractionated, the analytical sensi-
tivity and TTP were superior when testing plasma. Centrifugation had no effect on DNA availability, whereas the presence of clot
material significantly lowered the concentration (P 0.028). Technically, there are nomajor differences in the molecular pro-
cessing of serum and plasma, but the formation of clot material potentially reduces available DNA in serum. During disease,
AspergillusDNA burdens in blood are often at the limits of PCR performance. Using plasmamight improve performance while
maintaining the methodological simplicity of serum testing.
Invasive aspergillosis (IA) represents a serious health problem forthe immunocompromised patient, especially those undergoing
cancer chemotherapy or receiving corticosteroid therapy or im-
munosuppression to avoid allograft rejection or solid organ rejec-
tion. Aspergillus fumigatus is a ubiquitous mold and the most fre-
quent cause of aspergillosis in humans, causing awide spectrumof
diseases ranging from allergies to severe life-threatening invasive
manifestations. Spores of A. fumigatus enter the body through
inhalation, and infection primarily occurs in the lungs. Accurate
diagnosis of IA remains difficult. Given the limitations of clinical
signs and the difficulty in obtaining appropriate specimens for
diagnosis, a significant proportion of cases remain undetected,
resulting in late or inappropriate therapy and increased mortality
rates as high as 90% with cerebral disease (1). Hence, there is an
urgent need for an accurate and standardized approach for diag-
nosing IA.
The performance of mycological diagnostics when testing se-
rum or plasma samples is assumed to be similar. The revised Eu-
ropean Organization for Research and Treatment of Cancer/In-
vasive Fungal Infections Cooperative Group and the National
Institute of Allergy and Infectious Diseases Mycoses Study Group
(EORTC-MSG) definitions for invasive fungal infections include
galactomannan (GM)-enzyme immunoassay (EIA) for testing of
both serum and plasma (2), although the testing of plasma with
this assay has not been validated by the manufacturer. A study
comparingGM-EIAperformance in serumandplasma confirmed
that the testing of plasma using the same thresholds was appropri-
ate, but interestingly, the mean index generated by testing plasma
was significantly higher than that for serum (0.315 versus 0.279;
P 0.0398 [3]).Moreover, four possible IA caseswould have been
classified as probable IA had plasma been tested. The authors hy-
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pothesized that differences in indices could be attributed to the
formation of the blood clot potentially ensnaring some of the GM
within the sample taken for serum testing. It is conceivable that
the same might be true for extracellular DNA, the Aspergillus tar-
get in the cell-free fraction of host blood, which would thereby
affect PCR performance.
This paper describes further efforts of the EuropeanAspergillus
PCR Initiative (EAPCRI) to evaluate the analytical performance of
plasma and serum samples through the blinded distribution of
simulated panels, as described previously for whole blood and
plasma (4, 5). We report data on the differences in analytical per-
formance associated with different sample types (plasma versus
serum) and on how differences in the initial formation of the
sample types (clot versus no clot) and sample processing (whole-
blood centrifugation) affected the availability of DNA within the
cell-free sample itself.
In a companion paper (6) to this analytical in vitro study, a
further multicenter clinical study, which compares the perfor-
mance of plasma and serum, was performed in parallel (6).
MATERIALS AND METHODS
DNAsourcematerial.DNAwas obtained froma sporulating culture ofA.
fumigatus (strain ATCC 1022). Conidia were harvested, and DNA was
extracted as described before (5).
Participants. The participants comprised 8 laboratories representing
the EAPCRI core facilities and an extended group of an additional 15
laboratories. To maintain impartiality throughout the analytical process,
all centers were given a numerical code to allow a blinded review of indi-
vidual methodological procedures, determination of performance, and
statistical analysis.
Panels. All EDTA whole-blood and clotted-blood samples were ob-
tained from consenting healthy volunteers and screened for the presence
of infectious agents, as per protocol of the Institute of Transfusion Med-
icine, Würzburg University Hospital, (Würzburg, Germany), and ap-
proved by the local ethics review board. Serum and plasma were fraction-
ated by centrifugation and pooled, respectively, before being distributed
to Public Health Wales, Microbiology Cardiff, Cardiff, United Kingdom,
to develop the panel. To avoid airborne contamination, all processing of
material took place in a category 2 laminar flow cabinet. The panel was
validated through testing with an in-house Aspergillus-specific real-time
PCR (7). The panels were distributed on dry ice by a courier. The partic-
ipating centers were asked to confirm receipt, comment on the state of the
panel (frozen or thawed), and keep specimens frozen at 80°C until
testing.
Analytical testing was performed by using a four-part process, ex-
plained below.
(i) Assessment of analytical performance of Aspergillus PCR meth-
ods when testing serum. Initially, serum was divided into 3  35-ml ali-
quots; one aliquot was retained to provide a negative-control sample, while
two aliquots were spiked with 100 and 10 genome equivalents (ge) of A.
fumigatus DNA per milliliter of serum. The 35-ml serum batches were
further divided into 1-ml aliquots and frozen at80°C until distribution
on dry ice to the 23 centers. This panel was a quality control (QC) exercise
designed to confirm the findings of the previous research investigating
serum, in doing so providing a reference for a comparisonwith the plasma
results but also determining centers with optimal results for the analyses
of further panels, including the analysis of plasma samples (5).
(ii) Assessment of analytical performance ofAspergillus PCRmeth-
odswhen testing plasma.Plasmawas divided in eight 12-ml aliquots; two
aliquots were retained to provide negative-control samples, while six ali-
quots were spiked with various concentrations of A. fumigatus genomic
DNA (1,000, 100, 50, 10, 5, 1, and 0 ge/ml) and divided into 1-ml aliquots.
The panels were distributed on dry ice to the 8 EAPCRI core centers for
testing. In keepingwith previous studies, the threshold of detection, based
on 95% variance, was set at 10 ge/ml (5).
(iii) Assessment of DNA availability in serum/plasma with whole-
blood spiking. DNA was spiked into blood collected into an EDTA Va-
cutainer and into a Vacutainer without any anticoagulant immediately
after sampling but before centrifugation. Blood was spiked with various
concentrations of genomic A. fumigatus DNA (100, 50, 10, and 0 ge/ml;
Fig. 1). Both the EDTA and clotted-blood Vacutainers were left for a
minimum of 30 min at room temperature to allow the blood without
anticoagulants to clot. The Vacutainers were then centrifuged (3,500 g
for 5min) to separate the cell-free fractions, which were pooled according
to sample type and initial concentration of fungal burden. Each sample
was then divided into 0.5-ml aliquots (potential target burdens, 50, 25, 5,
and 0 ge) and frozen at80°C prior to distribution on dry ice. Serum and
plasma samples were shipped on dry ice to the 8 EAPCRI core centers.
(iv) Investigating the effects of clot formation and blood fraction-
ation on the availability of A. fumigatus genomic DNA. The following
experiments were performed in a two-center study in Cardiff and Würz-
burg using identical spiking protocols, described below.
Impact of centrifugation. Two 4-ml aliquots of serum and plasma
were spikedwith 100 ge ofA. fumigatusDNA.An aliquot of plasma and an
aliquot of serum were centrifuged at 3,500 g for 5 min, mimicking the
centrifugation process necessary to fractionate blood samples and poten-
tially identifying any losses associated with this process. The other aliquot
of plasma and serum, equivalent to a direct spike control, remained un-
touched at ambient temperature until further processing by extraction.
DNAwas extracted from aminimumof three replicates of 0.5ml of serum
and 0.5ml of plasma that were spiked but not centrifuged and aminimum
of three replicates of 0.5 ml of serum and 0.5 ml of plasma that were both
spiked and centrifuged. DNA was extracted using the in-house protocols
of both centers (8, 9). Briefly, in Cardiff, Aspergillus DNA was extracted
using the Qiagen EZ1 DSP virus kit, as per the manufacturer’s instruc-
tions, with DNA eluted in 60 l; in Würzburg, the QIAamp UltraSens
virus kit (Qiagen) was used, as described by the manufacturer, and DNA
was eluted in 70 l. Both protocols comply with the EAPCRI recommen-
dations for testing serum (5). PCR was performed in duplicate and in-
cluded an internal control to measure PCR inhibition.
Impact of clot formation. Immediately after bloodwas drawn, 4ml of
EDTAwhole blood and 4ml of clotted bloodwere spikedwith 100 ge ofA.
fumigatusDNA. The clotted blood was left at ambient temperature for 30
min to coagulate, while the EDTA blood remained untouched at room
temperature for the same period. The samples were then centrifuged at
3,500  g for 5 min. After centrifugation, a minimum of three 0.5-ml
aliquots of plasma and serum and the cell pellet from the EDTA whole-
blood samples were extracted using local protocols, and DNA was eluted
in 100 l. The clot was not processed, as no EAPCRI-validated proce-
dures are currently available to do so. PCR was performed in both centers
using in-house amplification protocols and an inhibition control, all in
accordance with EAPCRI guidelines (5).
Statistical analysis. Centers were requested to return both qualitative
(positive/negative) and quantitative (quantification cycle [Cq]) results
within a designated time frame and provide detailed protocols for their
DNA extraction and PCR amplification systems. The information re-
quired included sample volume used, extraction method, DNA elution
volume, PCRmethod, PCR target, PCR template input volume, PCR total
reaction mixture volume, PCR amplification platform, and internal con-
trol PCR results.
The correlation between Cq and genomic load was estimated by linear
regression. The Cq was the dependent variable, whereas the explanatory
variables were (i) the genomic load (as log10 genomic DNA), (ii) the
spiked sample type (as a binary variable for serumor plasma), and (iii) the
interaction between genomic load and fluid. A multilevel mixed-effects
model was performed, using the centers as a grouping variable. This
model was comparable to a simplified calibration curve, also comparing
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the calibration lines concerning serum and plasma. Themodel was graph-
ically reported.
In addition, bivariate linear regressionwas performed to analyze possible
associations between PCR sensitivity and selected covariates (Table 1).
RESULTS
(i) Assessment of analytical performance of Aspergillus PCR
methods when testing serum. The serum analysis in this QC
panel compared favorably with the previous EAPCRI serum eval-
uation (5). All 23 centers were able to reproducibly detect the
sample that was spiked with 100 ge and generate negative results
when testing the sample not containingAspergillusDNA. Samples
spiked with 10 ge/ml generated an overall positivity rate of 74%
(17/23 centers) and a positivity rate of 82% (14/17) in centers that
were strictly in accordance with EAPCRI recommendations for
serum. Five out of the 6 centers that were not in accordance with
EAPCRI recommendations were unable to detect 10 ge/ml. Cen-
ters that were unable to detect the 10 ge/ml did not routinely
process serum samples (6/6) or used serum volumes of 0.5 ml
(5/6; volume range, 0.1 to 0.2 ml of serum). In addition, these
centers used only a small portion of their original serum sample
volume in the subsequent PCR assay (mean 7.9%, range, 1% to
25%), compared to amean volume of 24.4% (range, 16% to 82%)
for centers that were able to detect 10 ge/ml (P 0.028).
(ii) Assessment of analytical performance ofAspergillusPCR
methods when testing plasma. All centers that had received this
plasma panel were requested to adhere to the EAPCRI guidelines
for serum testing, and their positivity rates in the related QC se-
rum panel were 100%, 100%, and 0% (100, 10, and 0 ge/ml, re-
spectively).
Table 2 summarizes the results of the 8 centers. No samples
FIG 1 Flow diagram highlighting the process for determining the availability
of Aspergillus DNA in serum and plasma samples post-blood fractionation.
TABLE 1 Bivariate analysis for the sensitivity of Aspergillus PCR testing
spiked plasma specimens distributed to 8 EAPCRI core centersa
Variable Z scoreb P value
No. of plasma samples analyzed/mo 1.61 0.107
Plasma starting vol 2.50 0.01c
DNA elution vol 0.65 0.513
Ratio starting plasma vol to elution vol 2.32 0.02c
Total PCR vol 2.64 0.01c
Template vol 1.47 0.141
Use of internal control 4.90 0.00c
Use of2 replicates 2.31 0.02c
% of eluate vol used in PCR 0.95 0.343
a All continuous and binary center-specific covariates were included into the basic
model.
b With a negative Z score, the variable tended to exert a favorable effect on the PCR
assay.
c Covariates exerting a significant effect (P 0.05) and an absolute Z score of1.96.
TABLE 2 Aspergillus PCR performance using plasma samples spiked
with different fungal loadsa
Sample
no.
Burden
(ge/ml)
95% sample
variance
Positivity
rate (%)
Mean Cq
(95% CI) SE
1 1,000 939.6–1,060.4 100 32.4 (30.7–34.0) 0.70
2 100 80.8–119.2 100 36.1 (34.1–38.1) 0.84
3 50 36.4–53.6 100 36.9 (35.1–38.7) 0.75
4 10 4.0–16.0 100 39.00 (37.1–40.9) 0.79
5 5 0.8–9.2 100 39.9 (37.8–42.0) 0.88
6 1 0–2.92 8.3 40.0b NAc
7, 8 02 NA 0 No signal NA
a Plasma samples 1 to 8 were spiked with different fungal burdens (genome equivalents
[ge]/ml of plasma).
b Plasma 6 was positive in one center in a single sample only.
c NA, not available.
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were found to be inhibitory to PCR amplification. All 8 centers
achieved 100% positivity for fungal burdens between 5 ge/ml and
1,000 ge/ml, while the sample spiked with 1 ge/ml was positive in
a single sample at one center only (Fig. 2). Six out of 8 centers
stated that they use either serumor plasma or both in their routine
diagnostic procedures (2 centers mainly tested bronchoalveolar
lavage fluid).
The centers used between 0.1 ml and 1 ml (mean, 0.5 ml) of
plasma for subsequentDNAextraction, 50 to 100l (mean, 60l)
for the elution volume, and 2 to 15 l (mean, 8.7 l) for the
template volume in their PCR assays. In bivariate analyses, we
observed significant positive correlations between PCR sensitivity
and the volume of plasma used for DNA extraction, the ratio
between the volume of plasma used for extraction and the subse-
quent elution volume, the reactionmixture volume used for PCR,
the analysis of 2 replicates, and the use of an internal control
(Table 1).
To provide complete Cq values for a range of different plasma
volumes, a linear mixedmodel was used, which predictsCq values
for hypothetical plasma volumes (0.1 ml to 0.5 ml) and various A.
fumigatus DNA concentrations (5 to 1,000 ge/ml). The model
shows that both plasma volume andDNA load influenceCq values
(e.g., predicted Cq values for 5 ge/ml ranged depending on the
plasma volume between 37.6 and 40.7 [Table 3]).
(iii) Assessment of DNA availability in serum/plasma with
whole-blood spiking. In order tomeasure the availability of DNA
in the cell-free fraction post-whole-blood processing, an addi-
tional panel, consisting of 4 serum samples and 4 plasma samples,
was shipped to the 8 core EAPCRI centers. Our linear model
showed that while the slope for PCR from plasma and serum did
not differ significantly (P  0.381), the plasma intercept was 4.3
cycles lower (standard error, 1.38; 95% confidence interval
6.996 to 1.585) than the serum intercept (Z score  3.11,
P 0.002). Interestingly, this shift in Cq values was achieved at all
DNA concentrations tested (50, 25, and 5 ge/ml; Fig. 3). No inhi-
bition was observed. Center-specific methodological details are
shown in Table 4. The individual performance of each center in
this panel was significantly associated with the volume of sample
used for DNA extraction. While both centers using 0.2 ml of se-
rum or plasma achieved suboptimal sensitivity, as the serum sam-
ple spiked with 5 ge/ml was not detected, the centers using 0.5
ml of plasma and serumwere able to detect this sample as positive
(P 0.001) (Table 4). In addition, we observed a trend that lab-
oratories that routinely test serum or plasma by Aspergillus PCR
achieved higher sensitivity (P 0.07).
(iv) Investigating the effects of clot formation and blood
fractionation on the availability of A. fumigatus genomic DNA.
In order to identify any potential loss of DNA during centrifuga-
tion necessary to fractionate blood samples, the recovery of DNA
from spiked serum and plasma specimens that were centrifuged at
3,500  g was compared to that of spiked samples that were not
centrifuged (Fig. 4). In both centers, there were no significant
differences in Cq values between centrifuged or noncentrifuged
samples for either plasma or serum (Table 5). These results dem-
onstrate that centrifugation at 3,500  g is not sufficient to sedi-
ment free DNA from serum and plasma.
Interestingly, in both centers, plasma obtained after centrifu-
gation of spiked EDTA blood samples showed earlier Cq values
than those with serum obtained from the corresponding clotted-
blood samples (difference of mean Cq values between plasma and
serum, 2.26; standard error, 0.45; P 0.0002). The concentration
of genomic DNA added to the PCR was significantly lower (P 
FIG 2 Descriptive statistics for Aspergillus real-time PCR crossing points
when testing plasma samples containing various concentrations of A. fumiga-
tus genomic DNA. Means (closed diamonds), 95% confidence intervals of the
means (vertical bars), and single observations (open circles) are shown for
each fungal load.
TABLE 3 Influence of sample volume (0.1 to 0.5 ml) on Aspergillus real-
time PCR crossing points when testing plasma samples containing a
range of A. fumigatus genomic DNA concentrations (5 to 1,000 ge/ml)a
Plasma vol (ml)
Fungal load (ge/ml of plasma)
5 10 50 100 1,000
0.1 40.68 39.70 37.43 36.45 33.21
0.2 39.90 38.92 36.65 35.67 32.42
0.3 39.11 38.14 35.86 34.89 31.64
0.4 38.33 37.35 35.08 34.11 30.86
0.5 37.55 36.57 34.30 33.32 30.07
a The prediction of Cq values was calculated using a linear mixed model.
FIG 3 Comparison of Aspergillus real-time PCR when testing serum and
plasma samples containing various fungal loads using a linear mixed model.
Data are shown after the regression of the Cq value versus the fungal genomic
burden, with serum or plasma as a binary covariate.
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0.028) in serum samples post-clot formation (mean, 1.9 copies;
standard deviation [SD], 0.8) compared to DNA extracted from
serum not influenced by clot formation (mean, 4.2 copies; SD,
1.3). Although it is likely that a substantial amount ofA. fumigatus
DNA is bound during blood clot formation and consequently is
unavailable for DNA extractions using serum, it was not possible
to test the clot material, as optimized protocols are not available,
and technical limitations prevent the processing of the entire clot
material, which in this scenario was 2 ml in volume. However,
whole-blood cell pellets from centrifuged EDTAVacutainers con-
taining peripheral bloodmononuclear cells were tested. Relatively
small amounts ofA. fumigatusDNA (mean, 0.4 input copies) were
detectable in samples at both centers (center 1, 1/4 samples posi-
tive [threshold cycle {CT} value, 51.9 cycles], center 2, 2/5 samples
positive [CT values, 40.2 and 42 cycles]), although it appears that
themajority of theDNA remains in the plasma fraction (mean, 3.3
input copies).
DISCUSSION
The European Aspergillus PCR Initiative (EAPCRI) has published
standards for Aspergillus PCR and protocols for detecting Asper-
gillusDNA inwhole blood (4) and serum (5). The identification of
the critical stages of Aspergillus DNA extraction from both speci-
men types allowed the EAPCRI to propose a protocol that helps
ensure optimal performance of Aspergillus PCR across laborato-
ries. However, no such data exist for plasma, and no direct com-
parison between plasma and serum specimens has been per-
formed. Thus, EAPCRI continued its efforts to evaluate the
analytical performance of plasma compared with serum samples
through the blinded distribution of simulated panels. In parallel, a
multicenter clinical study was performed to compare the detec-
tion of A. fumigatus DNA isolated from plasma and serum ob-
tained from hematological patients (6).
Plasma specimens were spiked with A. fumigatus genomic
DNA. The group of 8 EAPCRI core laboratories was able to dem-
onstrate that the Cq values obtained from plasma were signifi-
cantly lower (P 0.002, Fig. 3) thanCq values from serum (50, 25,
and 5 ge).
Almost 15 years ago, Loeffler et al. (10) compared the sensitiv-
ities ofA. fumigatusDNAdetection fromplasma andwhole blood.
Although plasma and whole-blood samples spiked with Aspergil-
lus conidia showed an identical lower detection limit (10 CFU),
the sensitivity of plasma PCR was inferior to that of PCR per-
formed on whole-blood samples obtained from patients with
proven IA.However, bothDNAextraction andPCRamplification
technology have advanced over the past decade. In addition, the
quality of molecular diagnostics has advanced through numerous
external quality assessment initiatives, including the EAPCRI, the
MinimumInformation for Publication ofQuantitativeReal-Time
PCR Experiments (MIQE) guidelines (11), and the Quality Con-
trol for Molecular Diagnostics (QCMD) (http://www.qcmd.org).
In a recent study comparing EAPCRI methods for the testing of
serum and whole blood, there was a trend toward superior sensi-
tivity when testing whole blood, but this did not reach statistical
significance, and any benefit was outweighed by the simplicity of
testing serum (8).
The current study demonstrated that after spiking whole
blood, the PCR testing of plasma samples showed superior sensi-
tivity to that of serum (P 0.002, Fig. 3). To our knowledge, no
data exist comparing the detection ofA. fumigatusDNAdetection
in both serum and plasma. Lau et al. (12) showed that Candida
DNAwas detected more often in serum (71%) and plasma (75%)
than in whole blood (54%) in a study of 109 patients with candi-
demia. However, there was no significant difference between
plasma and serum, possibly because of the relatively small num-
bers of serum and plasma specimens that were tested (n 29 and
24, respectively) or the differences in fungal diseasemanifestation.
With respect to IA, the concentration of galactomannan as deter-
mined by EIA was shown in another study to be significantly
higher in plasma than in serum (P: 0.0398) and may have been
associated with clot formation (3).
The presence of compounds that may interfere withmolecular
assays is always a concern when processing clinical samples. Com-
pared to serum, plasma samples contain various coagulation fac-
tors that lead to the conversion of fibrinogen to fibrin and clot
TABLE 4 Details of the molecular procedures used by the EAPCRI centers investigating the performance of Aspergillus PCR when testing serum and
plasma
EAPCRI
center no.
No. of serum
samples/mo
DNA extraction
vol (ml) DNA extraction system
Vol (l) of:
PCR target
gene
Sensitivity (%)
in:
Elution Template PCR Serum Plasma
1 0 0.2 MagNA Pure 50 10 20 18S 66.7 100
2 80 1 QIAamp UltraSens virus 70 10 21 ITS 100 100
3 40 1 QIAamp UltraSens virus 38 10 21 ITS 100 100
4 15 0.2 QIAamp DNA mini 50 2 20 ITS 0 100
5 70 1 MagNA Pure total NA large volume 50 10 20 18S 100 100
6 240 0.5 EZ1 DSP virus 60 15 50 28S 100 100
7 50 0.5 MagNA Pure total NA large volume 100 5 20 28S 100 100
8 10 0.5 MagNA Pure viral NA large volume 50 10 50 28S 100 100
TABLE 5 Effect of centrifugation at 3,500 g on DNA recovery (as
indicated by mean Cq values) from spiked serum and plasma
specimensa
Material
Mean Cq value (cycles) at
center:
1 2
Plasma centrifuged 47.1 37.8
Plasma noncentrifuged 46.9 37.6
Serum centrifuged 46.1 37.2
Serum noncentrifuged 47.2 37.0
a The two centers revealed no significant differences in Cq values between centrifuged
and noncentrifuged plasma and serum samples, respectively (P 0.05).
Loefﬂer et al.
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FIG 4 (a) Flow diagram highlighting the process for determining the effect of centrifugation on the availability ofAspergillusDNA in serum and plasma samples.
(b) Flow diagramhighlighting the process for determining the effect of clot formation on the availability ofAspergillusDNA in serum compared to the processing
of plasma samples. IC, internal control.
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formation. Fibrinogen is a soluble protein, which is exclusively
found in plasma (normal range, 150 to 400 mg/dl) but not in
serum, and it has been shown to interact with magnesium, which
is also an essential component of the PCR (13). If this interaction
results in lowering the magnesium concentration, it might result
in PCR failure. All DNA extraction protocols used by the 8
EAPCRI study centers (Table 4) provided plasma DNA eluates
that yielded superior sensitivity and lower Cq values than those of
serum, indicating that the additional components in plasma had
no effect on PCR efficiency. In addition, the source of anticoagu-
lant is also important; García et al. (14) showed in rat blood that
when comparing sodium citrate, heparin, and tripotassium-
EDTA as anticoagulants, only tripotassium-EDTA did not inter-
fere with PCR used to diagnose IA.
The EAPCRI recommendations for Aspergillus PCR in serum
included the use of a minimum volume of 0.5 ml of serum as
starting material, DNA elution in a volume of 100 l (P 
0.003), and the use of an internal control (5). For plasma, bivariate
linear regression was used to evaluate similar covariates, finding
that there was a statistically significant positive association be-
tween PCR sensitivity and larger sample volumes (0.5 ml of
plasma), the use of 2 replicates (from a single eluate), and an
internal control. While the DNA elution volume itself is not sig-
nificantly associated with PCR sensitivity, the ratio of the initial
plasma sample volume to the subsequent elution volume was sig-
nificantly associated (Z score  2.32, P  0.02, Table 1). All 8
core centers complied with EAPCRI serum recommendations on
elution volume (100l [5]), so a correlation with PCR sensitiv-
ity is to be expected. However, the use of an internal control was
correlated and found to be statistically significant. Although this
parameter is only indirectly associated with the detection of A.
fumigatus DNA, it reflects the degree of diligence and accuracy of
an individual laboratory.
Interestingly, A. fumigatus genomic DNA, spiked into EDTA
whole blood and left untouched for 30 min, was detectable in
small amounts in some leukocyte pellets and in the cell-free frac-
tion. This suggests that circulating extracellular DNA reaches the
cell pellet either by gravitational force or due to binding to leuko-
cyte surface receptors. Indeed, Bennett et al. (15) showed that
there is a common binding site for DNA on white blood cells.
However, in a comparison to the detection ofA. fumigatusDNA in
serum clots, only 3/9 leukocyte pellets showed weak PCR-positive
results, whereas McCulloch et al. (16) reported significantly more
AspergillusDNAdetectable in serum clots than that in the cell-free
fraction (P  0.001; 95% CI, 2.24 to 6.48). These authors found
that the average Cq value for the clot sample was 2.38 cycles lower
than that for EDTA blood and 3.69 cycles lower than that for
serum. While this equates to 7.9- and 12-fold increases in DNA
yield from the clot in EDTA blood and serum, respectively, diffi-
culties in processing these samples limit their use in routine prac-
tice. This observationmight partially explain our observation that
Cq values fromnative serum (used before clotting) developed con-
sistently later thanCq values obtained fromnative plasma samples,
which were spiked with identical number of genome equivalents.
In conclusion, the analytical sensitivity of plasma, as deter-
mined by a multicenter evaluation of PCR-based detection of A.
fumigatus DNA, is superior to that with serum. Recommenda-
tions published by EAPCRI for serum (5), including sample vol-
ume, a minimum of duplicate PCR testing of each DNA extract,
and an internal control, can be applied to plasma.
To confirm the analytical findings described here, a parallel
multicenter clinical study (6) was performed. The retrospective
case-control study supports the findings of this analytical paper
and comes to the conclusion that there is a trend toward increased
sensitivity of plasma, although this did not reach significance (P
0.0897), and positivity was most frequently earliest when testing
plasma by PCR.
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